Table 1.
Study characteristics of included RCTs
| Study | Publication year | Indication | Intervention | Control | Initial Met dose (/day) | Max Met dose (/day) |
|---|---|---|---|---|---|---|
| Rowan et al. (MiG) [8] | 2008 | GDM | Met (±insulin) | Insulin | 500 mg or 1000 mg | 2500 mg |
| Niromanesh et al. [75] | 2012 | GDM | Met (±insulin) | Insulin | 1000 mg | 2500 mg |
| Spaulonci et al. [76] | 2013 | GDM | Met (±insulin) | Insulin | 1700 mg | 2550 mg |
| Tertti et al. [26] | 2013 | GDM | Met (±insulin) | Insulin | 500 mg | 2000 mg |
| Ainuddin et al. [10] | 2015 | GDM | Met (±insulin) | Insulin | 500 mg | 2500 mg |
| Rowan et al. (MiG TOFU) [22] | 2018 | GDM | Met (±insulin) | Insulin | ||
| Eid et al. [27] | 2018 | GDM | Met | Insulin | 500 mg | 2500 mg |
| Dunne et al. (EMERGE) [35] | 2022 | GDM | Usual care + Met | Usual care + placebo | 500 mg | 2500 mg |
| Ainuddin et al. [9] | 2015 | T2DM | Met (±insulin) | Insulin | 500 mg | 2500 mg |
| Feig et al. (MiTy) [31] | 2020 | T2DM | Insulin + Met | Insulin + placebo | 500 mg | 2000 mg |
| Vanky et al. (PregMet) [43] | 2010 | PCOS | Met | Placebo | 1000 mg | 2000 mg |
| Løvvik et al. (PregMet2) [24] | 2016 | PCOS | Met | Placebo | 1000 mg | 2000 mg |
| Syngelaki et al. [17] | 2016 | Obesity | Met | Placebo | 1000 mg | 3000 mg |
| Dodd et al. (GRoW) [47] | 2019 | Overweight Obesity | Met | Placebo | 500 mg | 2000 mg |
| Valdés et al. [48] | 2018 | Pre-gestational insulin resistance | Met | Placebo | 1700 mg | 1700 mg |
| Cluver et al. [74] | 2021 | Pre-eclampsia | Met | Placebo | 1500 mg | 3000 mg |
Met Metformin, RCTs randomized controlled trials, T2DM type 2 diabetes mellitus